Semma Therapeutics

Provider of bio-artificial pancreas for Type 1 Diabetes treatment

placeCambridge, Massachusetts, United States calendar_todayFounded 2015 groups58 employees language semma-tx.com

Registered entities

Innovation

10 patent families — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 347 times.

YearFilings
20181
20197
20208
20215
20233
20242
20251

Investor mix

12 investors on record; lead investors include T1D Fund, Eight Roads Ventures, Cowen; 2 have since exited.

Investor typeCountShare
Venture capital867%
Private equity18%
Bank & private debt18%
Other / undisclosed217%
Coming soon